SciMatics SciQSAR model for cytochrome P450 isoenzyme 2D6 (CYP2D6) substrates (human clinical data)

1. QSAR identifier

1.1 QSAR identifier (title)

SciMatics SciQSAR model for cytochrome P450 isoenzyme 2D6 (CYP2D6) substrates (human clinical data), Danish QSAR Group at DTU Food.

1.2 Other related models

MultiCASE CASE Ultra model for cytochrome P450 isoenzyme 2D6 (CYP2D6) substrates (human clinical data), Danish QSAR Group at DTU Food.

Leadscope Enterprise model for cytochrome P450 isoenzyme 2D6 (CYP2D6) substrates (human clinical data), Danish QSAR Group at DTU Food.

1.3. Software coding the model

SciQSAR version 3.1.00.

2. General information

2.1 Date of QMRF

January 2015.

2.2 QMRF author(s) and contact details

QSAR Group at DTU Food;

Danish National Food Institute at the Technical University of Denmark;

http://qsar.food.dtu.dk/;

qsar@food.dtu.dk

Sine Abildgaard Rosenberg;

National Food Institute at the Technical University of Denmark;

Trine Klein Reffstrup;

National Food Institute at the Technical University of Denmark;

Eva Bay Wedebye;

National Food Institute at the Technical University of Denmark;

Nikolai Georgiev Nikolov;

National Food Institute at the Technical University of Denmark;

Marianne Dybdahl;

National Food Institute at the Technical University of Denmark.

2.3 Date of QMRF update(s)

2.4 QMRF update(s)

2.5 Model developer(s) and contact details

Tine Ringsted;

National Food Institute at the Technical University of Denmark;

Jay Russel Niemelä;

National Food Institute at the Technical University of Denmark;

Svava Ósk Jónsdóttir;

National Food Institute at the Technical University of Denmark;

Nikolai Georgiev Nikolov;

National Food Institute at the Technical University of Denmark;

Eva Bay Wedebye;

National Food Institute at the Technical University of Denmark;

Danish QSAR Group at DTU Food;

National Food Institute at the Technical University of Denmark;

http://qsar.food.dtu.dk/;

qsar@food.dtu.dk

2.6 Date of model development and/or publication

January 2014.

2.7 Reference(s) to main scientific papers and/or software package

Contrera, J.F., Matthews, E.J., Kruhlak, N.L., and Benz, R.D. (2004) Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modelling of the human maximum recommended daily dose. *Regulatory Toxicology and Pharmacology*, 40, 185 – 206.

SciQSAR (2009) Reference guide: *Statistical Analysis and Molecular Descriptors*. Included within the SciMatics SciQSAR software.

2.8 Availability of information about the model

The training set is non-proprietary and was compiled from the published literature (see 6.5 for more details). The model algorithm is proprietary from commercial software.

2.9 Availability of another QMRF for exactly the same model

3. Defining the endpoint

3.1 Species

Human (primarily clinical data).

3.2 Endpoint

QMRF 5. Toxicokinetics

QMRF 5. 8. Toxicokinetics. Metabolism (including metabolic clearance)

3.3 Comment on endpoint

The cytochrome P450 (CYP) superfamily of heme-containing enzymes plays a significant role in phase I metabolism of a wide range of endogenous compounds and xenobiotics. It is therefore an important factor in drug development and drug therapy to determine if a drug is metabolized by CYP enzymes. Beside drugs, CYP enzymes detoxify environmental compounds and chemicals in consumer products. They also have the ability to form reactive intermediates that can damage DNA, lipids and proteins, and potentially lead to tumor initiation and cancer after long term exposure. The human genome encodes 57 different CYP genes, with five of these enzymes being responsible for the metabolism of 95% of drugs, namely CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. The modulation of CYP activity by inhibition or induction of drugs or other chemicals can cause problems ranging from insufficient therapeutic effect to fatal toxic consequences.

The isoenzyme CYP2D6 is primarily expressed in the liver and the mucosa of the small intestine and is considered to be involved in the metabolism of 12–15% of prescribed drugs including antidepressants, antipsychotics, some antiarrhythmics, beta-blockers and analgesics. CYP2D6 is associated with substantial genetic polymorphism causing large inter-individual differences in enzyme activity, and the difference in CYP2D6 activity makes some people more vulnerable to CYP2D6 substrates because of inadequate excretion (poor metaboliser (PM)) or rapid excretion (ultrarapid metaboliser (UM)) of drugs. CYP2D6 also has the possibility of forming harmful intermediates.

The metabolism activity of CYP2D6 is, in many cases, facilitated by an ion pair interaction between an aspartic acid residue at the active site and a protonated nitrogen atom of the substrate. Substrates of CYP2D6 contain a basic nitrogen atom 5Å or 7Å from the point of oxidation with aromatic rings positioned coplanar in the substrate.

Data for this model is based on human clinical data for CYP2D6, primarily drugs, gathered from the literature.

3.4 Endpoint units

No units, 1 for positives and 0 for negatives.

3.5 Dependent variable

Human cytochrome P450 isoenzyme 2D6 (CYP2D6), substrates or non-substrates.

3.6 Experimental protocol

Data were either obtained from *in vivo* clinical experiments or various *in vitro* models like tissues slices, microsomes, cell cultures and purified and recombinant enzymes that have formed the basis for a clinical decision. Epidemiological observations and case studies may also have served as input for such decisions.

Since data is obtained from various sources a common protocol have not been used, please see references in 9.2 for further information on the experimental protocols.

3.7 Endpoint data quality and variability

As data for the training set were compiled from multiple sources and no common experimental protocol has been described a certain degree of variability in data exists. In addition to this the main part of the training set consist of human clinical data and this type of data is associated with a high degree of variability because of the many factors affecting humans, such as genetics, lifestyle etc.

4. Defining the algorithm

4.1 Type of model

This is a categorical (Q)SAR model based on calculated molecular descriptors, and if available the modeller's own or third-party descriptors or measured endpoints can be imported and used as descriptors.

This is a categorical (Q)SAR model made by use of the non-parametric discriminant analysis (DA) kernel method (see 4.5). The specific implementation is proprietary within the SciQSAR software.

4.3 Descriptors in the model

Molecular connectivity indices

Molecular shape indices

Topological indices

Electrotopological (Atom E and HE-States) indices

Electrotopological bond types indices

SciQSAR software provides over 400 built-in molecular descriptors. Additionally, SciQSAR makes it possible to import the modeller's own or third-party descriptors or use measured endpoints as custom descriptors.

4.4 Descriptor selection

The initial descriptor set is manually chosen by the model developer from the total set of built-in descriptors. Furthermore, the set of descriptors applied in the modelling by the program is on top of this selection determined by thresholds for descriptor variance and number of nonzero values likewise defined by the model developer.

86 descriptors were selected from the initial pool of descriptors by the system and used to build the model.

4.5 Algorithm and descriptor generation

For a binary classification problem SciQSAR uses discriminant analysis (DA) to make a (Q)SAR model. SciQSAR implements a broad range of discriminant analysis (DA) methods including parametric and non-parametric approaches. The classic parametric method of DA is applicable in the case of approximately normal within-class distributions. The method generates either a linear discriminant function (the within-class covariance matrices are assumed to be equal) or a quadratic discriminant function (the within-class covariance matrices are assumed to be unequal). When the distribution is assumed to not follow a particular law or is assumed to be other than the multivariate normal distribution, non-parametric DA methods can be used to derive classification criteria. The non-parametric DA methods available within SciQSAR include the kernel and k-nearest-neighbor (kNN) methods. The main types of kernels implemented in SciQSAR include uniform, normal, Epanechnikov, bi-weight, or tri-weight kernels, which are used to estimate the group specific density at each observation. Either Mahalanobis or Euclidean distances can be used to determine proximity between compound-vectors in multidimensional descriptor space. When the kNN method is used, the Mahalanobis distances are based on the pooled covariance matrix. When the

kernel method is used, the Mahalanobis distances are based on either the individual within-group covariance matrices or the pooled covariance matrix. (Contrera *et al*. 2004)

If the data outcome is continuous, regression analysis is used to build the predictive model. Within SciQSAR several regression methods are available: ordinary multiple regression (OMR), stepwise regression (SWR), all possible subsets regression (PSR), regression on principal components (PCR) and partial least squares regression (PLS). The choice of regression method depends on the number of independent variables and whether correlation or multicollinearity among the independent variables exists: OMR is acceptable with a small number of independent variables, which are not strongly correlated. SWR is used under the same circumstances as OMR but with greater number of variables. PSR is used for problems with a great number of independent variables. PCR and PLS are useful when a high correlation or multicollinearity exist among the independent variables. (SciQSAR 2009)

To test how stable the developed models are, SciQSAR have built-in cross-validation procedures (see 6.).

For this model, the kernel method was used.

4.6 Software name and version for descriptor generation

SciQSAR version 3.1.00.

4.7 Descriptors/chemicals ratio

In this model 86 descriptors were used. The training set consists of 746 compounds. The descriptor/chemical ratio is 1:8.7 (86:746).

5. Defining Applicability Domain

5.1 Description of the applicability domain of the model

The definition of the applicability domain consists of two components; the definition in SciQSAR and the in-house further refinement algorithm on the output from SciQSAR to reach the final applicability domain call.

1. SciQSAR

The first criterion for a prediction to be within the models applicability domain is that all of the descriptor values for the test compound can be calculated by SciQSAR. If SciQSAR cannot calculate each descriptor value for the test chemical no prediction value is given by SciQSAR and it is considered outside the model's applicability domain.

2. The Danish QSAR group

The Danish QSAR group has applied a stricter definition of applicability domain for its SciQSAR models. In addition to the applicability domain definition made by SciQSAR a second criterion has been applied for predictions generated from (Q)SAR models with a binary endpoint. For each prediction SciQSAR calculates the probability (p) for the test compound's membership in one of the two outcome classes (positive or negative). The probability of membership in a class is a measure of how well training set knowledge is able to discriminate a positive prediction from a negative prediction within the nearest space of the subject compound-vector. The probability of membership value is also a measure of the degree of confidence of a prediction. The Danish QSAR group uses this probability for a prediction to further define the model's applicability domain. Only positive predictions with a probability equal to or greater than 0.7 and negative predictions with a probability equal to or less than 0.3 are accepted. Positive predictions with a probability between 0.5 and 0.7 as well as negative predictions with a probability between 0.3 and 0.5 are considered outside the model's applicability domain. When these predictions are wed out the accuracy of the model in general increases at the expense of reduced model coverage. Furthermore, as SciQSAR does not define a structural domain, only predictions which were within either Leadscope structural domain (defined as at least one training set chemical within a Tanimoto distance of 0.7) or CASE Ultra structural domain (no unknown fragments for negatives and maximum 1 unknown fragment for positives) were defined as being inside the SciQSAR applicability domain.

5.2 Method used to assess the applicability domain

The system does not generate predictions if it cannot calculate each descriptor value for the test compound.

Only positive predictions with probability equal to or greater than 0.7 and negative predictions with probability equal to or less than 0.3 were accepted.

5.3 Software name and version for applicability domain assessment

SciQSAR version 3.1.00.

5.4 Limits of applicability

The Danish QSAR group applies an overall definition of structures acceptable for QSAR processing which is applicable for all the in-house QSAR software, i.e. not only SciQSAR. According to this definition accepted structures are organic substances with an unambiguous structure, i.e. so-called discrete organics defined as: organic compounds with a defined two dimensional (2D) structure containing at least two carbon

atoms, only certain atoms (H, Li, B, C, N, O, F, Na, Mg, Si, P, S, Cl, K, Ca, Br, and I), and not mixtures with two or more 'big components' when analyzed for ionic bonds (for a number of small known organic ions assumed not to affect toxicity the 'parent molecule' is accepted). Structures with less than two carbon atoms or containing atoms not in the list above (e.g. heavy metals) are rendered out as not acceptable for further QSAR processing. Calculation 2D structures (SMILES and/or SDF) are generated by stripping off accepted organic and inorganic ions. Thus, all the training set and prediction set chemicals are used in their non-ionized form. See 5.1 for further applicability domain definition.

6. Internal validation

6.1 Availability of the training set

Yes

6.2 Available information for the training set

CAS

SMILES

6.3 Data for each descriptor variable for the training set

No

6.4 Data for the dependent variable for the training set

All

6.5 Other information about the training set

746 compounds are in the training set: 247 substrates and 499 non-substrates.

Data for the training set was compiled from the following sources: Hodgson (2001), Rendric (2002), Skinner *et al.* (2003), Dong (2005), Koumis and Samuel (2005), Yap and Chen (2005), Skerjanic (2006), Peters *et al.* (2007), Urichuk *et al.* (2008), and Draper (2009).

6.6 Pre-processing of data before modelling

Only structures acceptable for SciQSAR were used in the final training set. That is, only discrete organic chemicals as described in 5.4 were used. In case of replicate structures, one of the replicates was kept if all the compounds had the same activity and all were removed if they had different activity. No further structures accepted by the software were eliminated (i.e. outliers).

6.7 Statistics for goodness-of-fit

SciQSARs own internal performance test of the model gave the following Cooper's statistics for predictions within the applicability domain as defined by SciQSAR (i.e. the first criterion described in 5.1):

- Sensitivity (true positives / (true positives + false negatives)): 100%
- Specificity (true negatives / (true negatives + false positives)): 94.8%
- Concordance ((true positives + true negatives) / (true positives + true negatives + false positives + false negatives)): 96.5%

6.8 Robustness – Statistics obtained by leave-one-out cross-validation

Not performed.

6.9 Robustness – Statistics obtained by leave-many-out cross-validation

SciQSAR's own internal 10-fold cross-validation (10*10% out) procedure was used for predictions within the applicability domain as defined by SciQSAR (i.e. the first criterion described in 5.1). As the probability domain was not applied (i.e. the second criterion described in 5.2) the accuracy of the predictions when applying this domain can be expected to be higher than reflected in these cross-validation results. This gave the following Cooper's statistics:

- Sensitivity (true positives / (true positives + false negatives)): 59.5%
- Specificity (true negatives / (true negatives + false positives)): 79.8%
- Concordance ((true positives + true negatives) / (true positives + true negatives + false positives + false negatives)): 73.1%

6.10 Robustness - Statistics obtained by Y-scrambling

Not performed.

6.11 Robustness - Statistics obtained by bootstrap

Not performed.

6.12 Robustness - Statistics obtained by other methods

Not performed.

7. External validation

7.1 Availability of the external validation set

7.2 Available information for the external validation set

7.3 Data for each descriptor variable for the external validation set

7.4 Data for the dependent variable for the external validation set

7.5 Other information about the validation set

7.6 Experimental design of test set

7.7 Predictivity – Statistics obtained by external validation

7.8 Predictivity – Assessment of the external validation set

7.9 Comments on the external validation of the model
External validation has not been performed for this model.

8. Mechanistic interpretation

8.1 Mechanistic basis of the model

The SciQSAR software provides over 400 calculated physico–chemical, electrotopological E-state, connectivity and other molecular descriptors. The descriptors selected for the model may indicate modes of action that are obvious for persons with expert knowledge about the endpoint.

8.2 A priori or posteriori mechanistic interpretation

A posteriori mechanistic interpretation. The descriptors selected for the model may provide a basis for mechanistic interpretation.

8.3 Other information about the mechanistic interpretation

9. Miscellaneous information

9.1 Comments

The model can be used to predict if a chemical is a substrate of the cytochrome P450 2D6 isoenzyme in humans.

9.2 Bibliography

Dong, B.J. (2005) Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. *Clin. Ther.*, 27:4, 1725–1751.

Draper, E. (2009) New drug bulletin: Budesonide and Formoterol (Symbicort-AstraZeneca), University of Utah Hospitals and Clinics, E. Fox, ed., Accessed 12 February 2009, Available at http://healthcare.utah.edu/pharmacy/bulletins/NDB_136.pdf.

Hodgson, E. (2001) In vitro human phase I metabolism of xenobiotics I: Pesticides and related chemicals used in agriculture and public health, September 2001. *J. Biochem. Mol. Toxicol.,* 15:6, 296–299.

Jónsdóttir, S.Ó., Ringsted, T., Nikolov, N.G., Dybdahl, M, Wedebye, E.B., Niemelä, J.R. (2012). Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis. *Bioorganic & Medicinal Chemistry* 20, 2042–2053.

Koumis, T., and Samuel, S. (2005) Tiotropium bromide: A new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. *Clin. Ther*., 27:4, 377–392.

Peters F.T., Dragan, C.A., Wilde, D.R., Meyer, M.R., Zapp, J., Bureik, M., and Maurer, H.H. (2007) Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 40-hydroxymethyl-alphapyrrolidinobutyrophenone. *Biochem. Pharmacol.*, 74, 511–520.

Rendic, S. (2002) Summary of information on human CYP enzymes: Human P450 metabolism data*. Drug Metabolism Reviews,* 34(1&2), 83–448.

Ringsted, T., Nikolov, N., Jensen, G.E., Wedebye, E.B., and Niemelä, J. (2009) QSAR Models for P-450 (2D6) Substrate Activity. *SAR and QSAR in Environmental Research*, 20:3, 309-325.

Skerjanec, A. (2006) The clinical pharmacokinetics of darifenacin. *Clin. Pharmacokinet*., 45:4 ,325–350.

Skinner, M.H., Kuan, H.Y., Pan, A., Sathirakul, K., Knadler, M.P., Gonzales, C.R., Yeo, K.P. Reddy, S., Lim, M., Ayan-Oshodi, M., and Wise, S.D. (2003) Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. *Clin Pharmacol Ther.,* 73:3, 170–177.

Urichuk, L., Prior, T.I., Dursun, S., and Baker, G. (2008) Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. *Curr. Drug Metab.,* 9, 410–418.

Yap, C. W., and Chen, Y. Z. (2005) Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines. *J. Chem. Inf. Model,* 45, 982-992.

9.3 Supporting information